Joseph S. Pagano, MD, has been awarded the fifth annual Hyman L. Battle Distinguished Cancer Research Award in recognition of his accomplishments in cancer research. Dr. Pagano is the director emeritus of UNC Lineberger Comprehensive Cancer Center.
Current nanomedicine research has focused on the delivery of established and novel therapeutics. But a UNC team is taking a different approach.
UNC Lineberger’s 36th annual scientific symposium drew large crowds, with over 450 participants.
UNC’s Seth Noar examines intersection of technology and health
Paul Armistead, MD, PhD, has received a grant of more than $396,000 from the National Heart, Lung and Blood Institute (part of the National Institutes of Health) to study leukemia stem cell-associated minor histocompatibility antigens.
UNC junior Molly DeCristo attended her first international scientific meeting, but not just as a participant. The American Association for Cancer Research (AACR) honored her poster with a rosette, judging it as “highly rated,” among the top 2.5 percent of those submitted.
A Wayne County woman doesn’t let cancer, its treatment or its recurrence get in the way of her plans to attend her oldest granddaughter’s high school graduation or her own 45th high school reunion.
Chapel Hill - A treatment for localized prostate cancer known as Intensity Modulated Radiation Therapy (IMRT) is better than conventional conformal radiation therapy (CRT) for reducing certain side effects and preventing cancer recurrence, according to a study published in the April 18, 2012 issue of the Journal of the American Medical Association. In 2012, approximately 241,740 American men will be diagnosed with prostate cancer.
CHAPEL HILL, N.C. - As the number of breast cancer survivors increases, now estimated at 2.8 million, more will be living with the chronic effects of cancer treatments or with advanced disease.
James Coghill, MD, has received a grant of more than $529,000 from the National Heart, Lung and Blood Institute (part of the National Institutes of Health) to study a promising target for new therapies to combat graft versus host disease, a serious complication of treatment for many blood cancers.